HISTORY
Building a Better Tomorrow, Every Day
Every day we are innovating and evolving into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.
2021
ACQUISITION
Alexion acquired by AstraZeneca. The AstraZeneca group focusing on rare diseases is created and named Alexion, AstraZeneca Rare Disease.
2020
ACQUISITION
Acquired Portola Pharmaceuticals, a commercial-stage biopharmaceutical company focused on life-threatening blood-related disorders
ACQUISITION
Acquired Achillion Pharmaceuticals, the company that began development of two oral factor D inhibitors
2019
APPROVAL
Treatment approved for adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)
ABOUT aHUSAPPROVAL
First complement inhibitor approved for adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD)
ABOUT NMOSD
KIM
LIVING WITH NMOSD
PARTNERSHIP
Established partnerships with Caelum Biosciences, Zealand Pharma, and Affibody
2018
APPROVAL
Treatment approved for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
ABOUT PNH
VICTOR
LIVING WITH PNH
ACQUISITION
Acquired Syntimmune, the company that began development of a treatment for rare IgG-mediated diseases
ACQUISITION
Acquired Wilson Therapeutics, the company that began development of a treatment for Wilson Disease
COMPANY MILESTONE
Opened global headquarters in Boston
2017
2016
COMPANY MILESTONE
Opened the Center of Excellence in New Haven
2015
APPROVAL
First treatment approved for patients with lysosomal acid lipase deficiency (LAL-D)
ABOUT LAL-DAPPROVAL
First treatment approved for patients with hypophosphatasia (HPP)
ABOUT HPP
EVIE
LIVING WITH HPP
ACQUISITION
Acquired sebelipase alfa, a potential treatment for patients living with LAL-D
2012
ACQUISITION
Acquired asfostase alfa, a potential treatment for patients living with HPP
2011
APPROVAL
First treatment approved for patients with atypical hemolytic uremic syndrome (aHUS)
ABOUT aHUS2007
APPROVAL
First treatment approved for patients with paroxysmal nocturnal hemoglobinuria (PNH)
ABOUT PNH
JOE
LIVING WITH PNH
1996
COMPANY MILESTONE
Alexion goes public with ticker ALXN
1992
COMPANY MILESTONE
Alexion founded in New Haven, CT
Related Topics
Help is out there and we’re not alone anymore.”JILL LIVING WITH aHUS